2024-513167-68-00已完成3 期
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 40
- 主要终点
- The primary endpoint for this study is Progression Free Survival (PFS), which is defined as the time from randomization until documented PD or death due to any cause, whichever occurs first. For the primary analysis of the primary endpoint, documented PD will be determined by the Investigator using RECIST v1.1.
研究概览
简要总结
To evaluate and compare the efficacy of Selinexor compared to placebo, as assessed by the investigator, as maintenance therapy in patients with advanced or recurrent endometrial cancer.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female, at least 18 years of age at the time of informed consent.
- •Histological confirmed endometrial cancer of the endometrioid, serous, or undifferentiated type. Carcinosarcoma of the uterus is also allowed.
- •Completed a single line of at least 12 weeks of taxane-platinum combination therapy for Stage IV disease or at first relapse and is in partial or complete remission according to RECIST v1.
- •This includes patients who received taxane-platinum combination therapy for primary Stage IV disease and patients who received taxane-platinum combination therapy for recurrent (i.e., relapse after primary therapy for early stage disease including surgery and/or adjuvant therapy) disease.
- •Must be able to initiate study drug 5 to 8 weeks after completion of their final dose of chemotherapy.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Hepatic function: total bilirubin up to 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN in patients without liver metastasis. For patients with known liver involvement of their tumor: AST and ALT ≤5 x ULN. b. Hematopoetic function: Absolute neutrophil count (ANC) ≥1.5 x 109/L; platelet count ≥100 x 109L; hemoglobin ≥9.0 g/dL. c. Renal function: estimated creatinine clearance (CrCl) of ≥30 mL/min, calculated using the Cockroft-Gault formula.
- •In the opinion of the Investigator, the patient must: a. Have a life expectancy of at least 12 weeks, and b. Be fit to receive experimental therapy
- •Premenopausal females of childbearing potential must have a negative pregnancy test (serum β human chorionic gonadotropin test) prior to the first dose of study drug. Female patients of childbearing potential must agree to use must agree to use highly effective methods of contraception throughout the study and for 3 months following the last dose of study drug.
- •Written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
排除标准
- •Has any sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear cell carcinomas.
- •Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety or compliance with the protocol.
- •Known contraindications to selinexor.
- •Known uncontrolled hypersensitivity to the investigational drug, or to its excipients.
- •Radiotherapy to the target lesion within the past 3 months prior to baseline imaging.
- •Persistent Grade 3 or 4 toxicity from previous chemotherapy and/or radiotherapy, with the exception of alopecia.
- •Active brain metastases (e.g., stable for <8 weeks, no adequate previous treatment with radiotherapy and/or surgery, symptomatic, requiring treatment with anti-convulsants. Corticoid therapy is allowed if administered as stable dose for at least 1 month before randomization).
- •Known unstable cardiovascular function: a. Symptomatic ischemia, or b. Uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on anti-arrhythmia are excluded; 1st degree atrioventricular block or asymptomatic left anterior fascicular block /right bundle branch block will not be excluded), or c. Congestive heart failure of New York Heart Association Class ≥3, or d. Myocardial infarction within 3 months
- •Females who are pregnant or actively breastfeeding.
- •Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral.
- •Active hepatitis C and/or B infection.
- •Received a blood or platelet transfusion during 4 weeks prior to randomization.
- •Patients unable to swallow tablets, patients with malabsorption syndrome, or any other GI disease or GI dysfunction that could interfere with absorption of study drug. A history of bowel obstruction requiring a nasogastric tube or intravenous infusion during the past 2 months is not allowed (except when this obstruction is caused by surgery or other non-malignant causes).
- •Psychiatric illness or substance use that would prevent the patient from giving informed consent or being compliant with the study procedures.
- •Patients unwilling or unable to comply with the protocol.
- •Persons who have been committed to an institution by official or judicial order.
- •Patients with dependency on the Sponsor, Investigator or study site.
- •Being treated with a concurrent cancer therapy.
- •Previous treatment with an XPO1 inhibitor.
- •Previous treatment with anti-PD1 or anti-PD-L1 immunotherapy (e.g., pembrolizumab).
- •Concurrent treatment with an investigational agent or participation in another clinical trial.
- •Patients who received any systemic anticancer therapy including investigational agents or radiation ≤3 weeks (or ≤5 half-lives of the drug [whichever is shorter]) prior to C1D
- •Palliative radiotherapy may be permitted for symptomatic control of pain from bone metastases in extremities, provided that the radiotherapy does not involve target lesions, and the reason for the radiotherapy does not reflect progressive disease (PD).
- •Major injuries or surgery within 14 days prior to C1D1 and/or planned surgery during the on-treatment study period.
- •Previous malignant disease, except patients with other malignant disease, for which the patient has been disease-free for at least 3 years. Concurrent other malignant disease except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma of the skin.
结局指标
主要结局
The primary endpoint for this study is Progression Free Survival (PFS), which is defined as the time from randomization until documented PD or death due to any cause, whichever occurs first. For the primary analysis of the primary endpoint, documented PD will be determined by the Investigator using RECIST v1.1.
The primary endpoint for this study is Progression Free Survival (PFS), which is defined as the time from randomization until documented PD or death due to any cause, whichever occurs first. For the primary analysis of the primary endpoint, documented PD will be determined by the Investigator using RECIST v1.1.
次要结局
- PFS, as assessed by a BICR, per RECIST v1.1
- Time to first subsequent therapy (TFST) and time to second subsequent treatment (TSST).
- Progression-free survival (PFS2)
- Disease-specific survival (DSS) and overall survival (OS)
- Disease-control rate (DCR; defined as best response of CR, PR, or SD for at least 16 weeks).
- European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire (QLQ)-C30 and EORTC QLQ-EN24.
- The safety and tolerability of study treatment will be evaluated based on AE reports, physical examination results (including vital signs), and clinical laboratory results by means of the occurrence, nature and severity of AEs.
研究者
Clinical Trial Information Desk
Scientific
Karyopharm Therapeutics Inc.
研究点 (40)
Loading locations...
相似试验
进行中（未招募）
3 期
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaEndometrial CancerNCT05611931Karyopharm Therapeutics Inc257
进行中（未招募）
1 期
A study of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal tumors (GISTs)EUCTR2017-004761-28-ESGrupo Español de Investigación en Sarcomas41
招募中
1 期
Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell LymphomasRelapsed or Refractory Peripheral T-cell LymphomasMedDRA version: 21.0Level: PTClassification code: 10001416Term: Adult T-cell lymphoma/leukaemia recurrent Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10001417Term: Adult T-cell lymphoma/leukaemia refractory Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10001413Term: Adult T-cell lymphoma/leukaemia Class: 100000004864CTIS2024-513295-18-00Fondazione IRCCS Istituto Nazionale Dei Tumori30
进行中（未招募）
1 期
Selinexor in patients with advanced thymoma and thymic carcinomaadvanced thymic epithelial tumour (TET) progressing after primary chemotherapyMedDRA version: 21.1Level: PTClassification code 10055108Term: Thymic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10043670Term: ThymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10043674Term: Thymoma malignant recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061031Term: Thymoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002612-40-DKDepartment of Oncology Rigshospitalet50
进行中（未招募）
1 期
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed/Refractory DLBCLMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851EUCTR2014-001977-15-GRKaryopharm Therapeutics, Inc.110